Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies

Lymphocyte-activation gene-3 (LAG-3), an immune checkpoint receptor, negatively regulates T-cell function and facilitates immune escape of tumors. Dual inhibition of LAG-3 and programmed cell death receptor-1 (PD-1) significantly improved progression-free survival (PFS) in metastatic melanoma patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Gide, Tuba N., Paver, Elizabeth C., Yaseen, Zarwa, Maher, Nigel, Adegoke, Nurudeen, Menzies, Alexander M., Pires da Silva, Ines, Wilmott, James S., Long, Georgina V., Scolyer, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558007/
https://www.ncbi.nlm.nih.gov/pubmed/37808404
http://dx.doi.org/10.1080/2162402X.2023.2261248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558007/
https://www.ncbi.nlm.nih.gov/pubmed/37808404
http://dx.doi.org/10.1080/2162402X.2023.2261248

Ejemplares similares